Drug profile · INN
donepezil hydrochloride
ADLARITY
donepezil hydrochloride (ADLARITY) is a acetylcholinesterase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: transdermal. Current US regulatory status: approved.
Drug details — donepezil hydrochloride
- US status
- approved
- Class
- —
- Route
- TRANSDERMAL
- Patents
- 0
- Programs
- 11
- Data quality
- 0.89
Quick answer
donepezil hydrochloride (ADLARITY) is a acetylcholinesterase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: transdermal. Current US regulatory status: approved.
Key facts
Mechanism of action
Acetylcholinesterase inhibitor
Primary target: Acetylcholinesterase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is donepezil hydrochloride?
donepezil hydrochloride (ADLARITY) is a acetylcholinesterase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: transdermal. Current US regulatory status: approved.
What is the brand name for donepezil hydrochloride?
ADLARITY is a marketed brand name for donepezil hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of donepezil hydrochloride?
donepezil hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.